Immunic (IMUX) Change in Account Payables (2013 - 2026)

Immunic has disclosed Change in Account Payables across 14 years of filings, most recently posting $1.1 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.1 million, up 152.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (up 702.6% YoY), and the FY2025 annual result was $1.2 million, down 60.67% from the prior year.
• Change in Account Payables came in at $1.1 million for Q1 2026 at Immunic, down from $2.2 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.3 million in Q4 2024 to a low of -$2.1 million in Q3 2024.
• The 5-year median for Change in Account Payables is $986000.0 (2023), against an average of $417000.0.
• Peak annual rise in Change in Account Payables reached 602.27% in 2023, while the deepest fall reached 530.77% in 2023.
• Immunic's Change in Account Payables stood at -$352000.0 in 2022, then jumped by 602.27% to $1.8 million in 2023, then climbed by 28.62% to $2.3 million in 2024, then retreated by 4.84% to $2.2 million in 2025, then tumbled by 49.58% to $1.1 million in 2026.
• The last three Change in Account Payables figures came in at $1.1 million (Q1 2026), $2.2 million (Q4 2025), and -$31000.0 (Q3 2025), per Business Quant data.